Baseline characteristics of patients receiving first-line therapy for CLL at enrollment in the Connect CLL Registry
| Characteristic . | Early POD . | Late POD . | No POD . | All patients . |
|---|---|---|---|---|
| N (% of total) | 209 (25.2) | 162 (19.5) | 458 (55.3) | 829 (100.0) |
| Age | ||||
| Median (range), y | 71.0 (41-91) | 67.5 (22-94) | 67.0 (27-99) | 68.0 (22-99) |
| ≥65 y, n (%) | 140 (67.0) | 93 (57.4) | 278 (60.7) | 511 (61.6) |
| ≥75 y, n (%) | 81 (38.8) | 35 (21.6) | 123 (26.9) | 239 (28.8) |
| Sex, n (%) | ||||
| Male | 137 (65.6) | 110 (67.9) | 280 (61.1) | 527 (63.6) |
| Female | 72 (34.4) | 52 (32.1) | 178 (38.9) | 302 (36.4) |
| Race | ||||
| Available, n | 204 | 157 | 443 | 804 |
| White, n (% of available) | 185 (90.7) | 143 (91.1) | 415 (93.7) | 743 (92.4) |
| African American, n (% of available) | 15 (7.4) | 13 (8.3) | 25 (5.6) | 53 (6.6) |
| Other, n (% of available) | 4 (2.0) | 1 (0.6) | 3 (0.7) | 8 (1.0) |
| Geographic region | ||||
| Available, n | 204 | 161 | 456 | 821 |
| West, n (% of available) | 42 (20.5) | 26 (16.1) | 67 (14.7) | 135 (16.4) |
| Midwest, n (% of available) | 65 (31.9) | 54 (33.5) | 137 (30.0) | 256 (31.2) |
| Northeast, n (% of available) | 24 (11.8) | 22 (13.7) | 56 (12.3) | 102 (12.4) |
| South, n (% of available) | 73 (35.8) | 59 (36.6) | 196 (43.0) | 328 (40.0) |
| Charlson comorbidity index, n (% of available) | ||||
| Low (≤2) | 115 (55.0) | 95 (58.6) | 264 (57.6) | 474 (57.2) |
| High (≥3) | 94 (45.0) | 67 (41.4) | 194 (42.4) | 355 (42.8) |
| Rai stage | ||||
| Available, n | 151 | 135 | 346 | 632 |
| 0-I, n (% of available) | 80 (53.0) | 82 (60.7) | 179 (51.7) | 341 (54.0) |
| II-IV, n (% of available) | 71 (47.0) | 53 (39.3) | 167 (48.3) | 291 (46.0) |
| Cytogenetic risk category* | ||||
| Available, n | 117 | 94 | 265 | 476 |
| Unfavorable, n (% of available) | 40 (34.2) | 40 (42.6) | 52 (19.6) | 132 (27.7) |
| Favorable, n (% of available) | 77 (65.8) | 54 (57.4) | 213 (80.4) | 344 (72.3) |
| Median TTP in all patients, mo | 12 | 37 | — | 21 |
| Median TTP after first-line FCR, mo | 16 | 38 | — | 26 |
| Median TTP after first-line BR, ms | 13 | 41 | — | 25 |
| Patients who received subsequent therapy and had available treatment data, n | 160 | 130 | — | 290 |
| TTNT in all patients, ms | 12 | 38 | — | 22 |
| Characteristic . | Early POD . | Late POD . | No POD . | All patients . |
|---|---|---|---|---|
| N (% of total) | 209 (25.2) | 162 (19.5) | 458 (55.3) | 829 (100.0) |
| Age | ||||
| Median (range), y | 71.0 (41-91) | 67.5 (22-94) | 67.0 (27-99) | 68.0 (22-99) |
| ≥65 y, n (%) | 140 (67.0) | 93 (57.4) | 278 (60.7) | 511 (61.6) |
| ≥75 y, n (%) | 81 (38.8) | 35 (21.6) | 123 (26.9) | 239 (28.8) |
| Sex, n (%) | ||||
| Male | 137 (65.6) | 110 (67.9) | 280 (61.1) | 527 (63.6) |
| Female | 72 (34.4) | 52 (32.1) | 178 (38.9) | 302 (36.4) |
| Race | ||||
| Available, n | 204 | 157 | 443 | 804 |
| White, n (% of available) | 185 (90.7) | 143 (91.1) | 415 (93.7) | 743 (92.4) |
| African American, n (% of available) | 15 (7.4) | 13 (8.3) | 25 (5.6) | 53 (6.6) |
| Other, n (% of available) | 4 (2.0) | 1 (0.6) | 3 (0.7) | 8 (1.0) |
| Geographic region | ||||
| Available, n | 204 | 161 | 456 | 821 |
| West, n (% of available) | 42 (20.5) | 26 (16.1) | 67 (14.7) | 135 (16.4) |
| Midwest, n (% of available) | 65 (31.9) | 54 (33.5) | 137 (30.0) | 256 (31.2) |
| Northeast, n (% of available) | 24 (11.8) | 22 (13.7) | 56 (12.3) | 102 (12.4) |
| South, n (% of available) | 73 (35.8) | 59 (36.6) | 196 (43.0) | 328 (40.0) |
| Charlson comorbidity index, n (% of available) | ||||
| Low (≤2) | 115 (55.0) | 95 (58.6) | 264 (57.6) | 474 (57.2) |
| High (≥3) | 94 (45.0) | 67 (41.4) | 194 (42.4) | 355 (42.8) |
| Rai stage | ||||
| Available, n | 151 | 135 | 346 | 632 |
| 0-I, n (% of available) | 80 (53.0) | 82 (60.7) | 179 (51.7) | 341 (54.0) |
| II-IV, n (% of available) | 71 (47.0) | 53 (39.3) | 167 (48.3) | 291 (46.0) |
| Cytogenetic risk category* | ||||
| Available, n | 117 | 94 | 265 | 476 |
| Unfavorable, n (% of available) | 40 (34.2) | 40 (42.6) | 52 (19.6) | 132 (27.7) |
| Favorable, n (% of available) | 77 (65.8) | 54 (57.4) | 213 (80.4) | 344 (72.3) |
| Median TTP in all patients, mo | 12 | 37 | — | 21 |
| Median TTP after first-line FCR, mo | 16 | 38 | — | 26 |
| Median TTP after first-line BR, ms | 13 | 41 | — | 25 |
| Patients who received subsequent therapy and had available treatment data, n | 160 | 130 | — | 290 |
| TTNT in all patients, ms | 12 | 38 | — | 22 |
TTNT, time to next therapy.
Cytogenetic risk category was defined by the hierarchical model. Unfavorable cytogenetic risk category was defined by del(11q) or del(17p) detected by interphase FISH or metaphase karyotype. Favorable-risk category was defined by the absence of both del(11q) and del(17p).